AI Health & Biotechnology

AI Blood Test Detects Early Liver Disease

Johns Hopkins researchers use liquid biopsy technology to identify fibrosis and cirrhosis before symptoms appear.

By Kronos News Desk··1 min read
A medical researcher holds a blood sample vial in a laboratory, with digital screens showing complex DNA data and AI analysis symbols.

A medical researcher holds a blood sample vial in a laboratory, with digital screens showing complex DNA data and AI analysis symbols.

Photo: Kronos News

Researchers at Johns Hopkins developed an AI-driven blood test to detect early-stage liver disease [1][2]. The liquid biopsy scans DNA fragments to identify markers of liver fibrosis and cirrhosis years before symptoms develop [1][3]. This marks the first time fragmentome technology has been applied to chronic non-cancer diseases [2]. Current diagnostic methods often require invasive biopsies or imaging that may miss early signs of scarring [2]. The new AI model analyzes "fragmentomes," which are patterns of cell-free DNA released into the bloodstream [3]. This approach could provide a scalable way to screen millions of people at risk for chronic liver conditions [1].

Editorial notes

Transparency note

Drafted with LLM; human-edited

AI assisted
Yes
Human review
Yes
Last updated

Risk assessment

Under review

Reviewed for sourcing quality and editorial consistency.

Sources

Related stories

View all

Topics

Get the weekly briefing

A concise briefing with selected stories and analysis.

No spam. Unsubscribe anytime. By joining, you agree to our Privacy Policy.

About the author

Kronos News Desk covers ai health & biotechnology and editorial analysis for Kronos News.